Jerrold H Levy

List of Publications by Year
in descending order

280 papers	22,580 citations	11908 72 h-index	10679 143 g-index
282 all docs	282 docs citations	282 times ranked	23920 citing authors

#	Article	IF	Citations
1	COVID-19 and its implications for thrombosis and anticoagulation. Blood, 2020, 135, 2033-2040.	0.6	1,892
2	Idarucizumab for Dabigatran Reversal. New England Journal of Medicine, 2015, 373, 511-520.	13.9	1,419
3	Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematology,the, 2020, 7, e438-e440.	2.2	1,186
4	Idarucizumab for Dabigatran Reversal â€" Full Cohort Analysis. New England Journal of Medicine, 2017, 377, 431-441.	13.9	858
5	Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. New England Journal of Medicine, 2010, 363, 1791-1800.	13.9	655
6	Guidelines for Perioperative Care in Cardiac Surgery. JAMA Surgery, 2019, 154, 755.	2.2	593
7	Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: Results of a randomized, double-blind trial. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 35-42.	0.4	554
8	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 1859-1865.	1.9	547
9	Thromboinflammation and the hypercoagulability of COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 1559-1561.	1.9	529
10	Inflammatory response to cardiopulmonary bypass. Annals of Thoracic Surgery, 2003, 75, S715-S720.	0.7	505
11	Coagulopathy in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2103-2109.	1.9	453
12	Coagulopathy of Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1358-1364.	0.4	412
13	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	2.5	366
14	Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. Journal of Thrombosis and Haemostasis, 2018, 16, 231-241.	1.9	333
15	Diagnosis and management of sepsisâ€induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1989-1994.	1.9	325
16	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflammation Research, 2020, 69, 1181-1189.	1.6	302
17	When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 623-627.	1.9	285
18	A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting. Circulation, 1995, 92, 2236-2244.	1.6	285

#	Article	IF	Citations
19	Blood Coagulation: Hemostasis and Thrombin Regulation. Anesthesia and Analgesia, 2009, 108, 1433-1446.	1.1	281
20	Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion, 2004, 44, 1143-1148.	0.8	276
21	Fibrinogen and Hemostasis. Anesthesia and Analgesia, 2012, 114, 261-274.	1.1	265
22	Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion, 2014, 54, 1389-1405.	0.8	259
23	Analyses of coronary graft patency after aprotinin use: Results from the international multicenter aprotinin graft patency experience (IMAGE) trial. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 716-730.	0.4	246
24	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open, 2017, 7, e017046.	0.8	230
25	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. New England Journal of Medicine, 2017, 376, 2032-2042.	13.9	225
26	Concepts of blood transfusion in adults. Lancet, The, 2013, 381, 1845-1854.	6.3	213
27	Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. British Journal of Anaesthesia, 2009, 102, 793-799.	1.5	209
28	Derangement of the endothelial glycocalyx in sepsis. Journal of Thrombosis and Haemostasis, 2019, 17, 283-294.	1.9	196
29	Comparison of threeâ€factor and fourâ€factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. Journal of Thrombosis and Haemostasis, 2014, 12, 1428-1436.	1.9	181
30	Cryoprecipitate therapy. British Journal of Anaesthesia, 2014, 113, 922-934.	1.5	161
31	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. Anesthesiology, 2013, 118, 1466-1474.	1.3	158
32	Perioperative Hemostatic Management of Patients Treated with Vitamin K Antagonists. Anesthesiology, 2008, 109, 918-926.	1.3	143
33	Multidisciplinary Approach to the Challenge of Hemostasis. Anesthesia and Analgesia, 2010, 110, 354-364.	1.1	142
34	Antithrombin: anti-inflammatory properties and clinical applications. Thrombosis and Haemostasis, 2016, 115, 712-728.	1.8	138
35	How I use fibrinogen replacement therapy in acquired bleeding. Blood, 2015, 125, 1387-1393.	0.6	137
36	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis, 2015, 114, 198-205.	1.8	132

#	Article	IF	Citations
37	A Phase III, Double-blind, Placebo-controlled, Multicenter Study on the Efficacy of Recombinant Human Antithrombin in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass. Anesthesiology, 2005, 102, 276-284.	1.3	129
38	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2019, 8, 728.	1.0	128
39	Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2020, 46, 089-095.	1.5	124
40	Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Critical Care, 2020, 24, 19.	2.5	124
41	Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 107-113.	0.4	121
42	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care, 2020, 24, 364.	2.5	118
43	Reversal agents for non-vitamin K antagonist oral anticoagulants. Nature Reviews Cardiology, 2018, 15, 273-281.	6.1	116
44	Rapid Evaluation of Coagulopathies After Cardiopulmonary Bypass in Children Using Modified Thromboelastography. Anesthesia and Analgesia, 2000, 90, 1324-1330.	1.1	115
45	Perioperative management of the bleeding patient. British Journal of Anaesthesia, 2016, 117, iii18-iii30.	1.5	113
46	Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. British Journal of Anaesthesia, 2016, 117, 41-51.	1.5	110
47	Pharmacologic preservation of the hemostatic system during cardiac surgery. Annals of Thoracic Surgery, 2001, 72, S1814-S1820.	0.7	107
48	Antifibrinolytic therapy: new data and new concepts. Lancet, The, 2010, 376, 3-4.	6.3	107
49	Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical Patients. Anesthesiology, 1994, 80, 1013-1018.	1.3	103
50	Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1. Anesthesia and Analgesia, 2007, 105, 918-925.	1.1	103
51	Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology, 2018, 128, 657-670.	1.3	103
52	ISTH guidelines for antithrombotic treatment in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225.	1.9	100
53	Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology, 2020, 132, 1238-1245.	1.3	99
54	Superoxide Production, Risk Factors, and Endothelium-Dependent Relaxations in Human Internal Mammary Arteries. Circulation, 1999, 99, 53-59.	1.6	98

#	Article	IF	Citations
55	Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion, 2006, 46, 919-933.	0.8	98
56	Bacterial contamination of platelets for transfusion: strategies for prevention. Critical Care, 2018, 22, 271.	2.5	97
57	Clinical Use of the Activated Partial Thromboplastin Time and Prothrombin Time for Screening. Clinics in Laboratory Medicine, 2014, 34, 453-477.	0.7	96
58	Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sanguinis, 2017, 112, 443-452.	0.7	94
59	Antifibrinolytic Therapy for Cardiac Surgery. Anesthesiology, 2015, 123, 214-221.	1.3	89
60	Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thrombosis Research, 2008, 122, 117-123.	0.8	88
61	Prothrombin Complex Concentrates in Trauma and Perioperative Bleeding. Anesthesiology, 2015, 122, 923-931.	1.3	88
62	Bleeding and management of coagulopathy. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 662-667.	0.4	84
63	Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesthesia and Analgesia, 2016, 122, 1287-1300.	1.1	84
64	Heparin Resistance â€" Clinical Perspectives and Management Strategies. New England Journal of Medicine, 2021, 385, 826-832.	13.9	83
65	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	1.0	83
66	Massive Transfusion Coagulopathy. Seminars in Hematology, 2006, 43, S59-S63.	1.8	82
67	The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opinion on Investigational Drugs, 2006, 15, 1077-1090.	1.9	81
68	Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2014, 7, 1333-1351.	1.1	81
69	Weal and flare responses to intradermal rocuronium and cisatracurium in humans. British Journal of Anaesthesia, 2000, 85, 844-849.	1.5	80
70	Novel Oral Anticoagulants. Anesthesiology, 2010, 113, 726-745.	1.3	80
71	Thrombomodulin in disseminated intravascular coagulation and other critical conditionsâ€"a multi-faceted anticoagulant protein with therapeutic potential. Critical Care, 2019, 23, 280.	2.5	79
72	Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Critical Care, 2015, 19, 203.	2.5	77

#	Article	IF	Citations
73	Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 927-939.	0.4	75
74	Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion, 2013, 53, 1120-1131.	0.8	70
75	Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal, 2015, 169, 751-757.	1.2	69
76	ISTH DIC subcommittee communication on anticoagulation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	1.9	69
77	Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSevenÂ®) and Fibrinogen (HaemocomplettanÂ® P). Anesthesia and Analgesia, 2008, 106, 732-738.	1.1	66
78	Patient Blood Management. Anesthesiology, 2020, 133, 212-222.	1.3	62
79	Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion, 1998, 38, 481-498.	0.8	61
80	The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy. Anesthesia and Analgesia, 2000, 90, 1076-1079.	1.1	61
81	Enhanced Recovery After Cardiac Surgery (ERAS Cardiac) Recommendations: An Important First Stepâ€"But There Is Much Work to Be Done. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 39-47.	0.6	61
82	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. Journal of Intensive Care Medicine, 2020, 35, 643-649.	1.3	60
83	Recombinant Human Transgenic Antithrombin in Cardiac Surgery. Anesthesiology, 2002, 96, 1095-1102.	1.3	57
84	Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. Anesthesiology, 2018, 128, 390-400.	1.3	57
85	Defining traumaâ€induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 740-747.	1.9	56
86	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest, 2021, 159, 2417-2427.	0.4	54
87	Anticoagulation management during cardiopulmonary bypass: A survey of 54 North American institutions. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1665-1666.	0.4	51
88	Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Review of Hematology, 2016, 9, 115-122.	1.0	51
89	Antithrombin Deficiency Increases Thrombin Activity After Prolonged Cardiopulmonary Bypass. Anesthesia and Analgesia, 2008, 106, 713-718.	1.1	50
90	Differential diagnoses for sepsisâ€induced disseminated intravascular coagulation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 415-419.	1.9	50

#	Article	IF	Citations
91	Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. Anesthesia and Analgesia, 2020, 130, 654-664.	1.1	49
92	The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. Journal of Thrombosis and Haemostasis, 2017, 15, 1317-1321.	1.9	46
93	Recent advances in the research and management of sepsis-associated DIC. International Journal of Hematology, 2021, 113, 24-33.	0.7	46
94	Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers. British Journal of Anaesthesia, 2018, 121, 758-767.	1.5	45
95	Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. Thrombosis and Haemostasis, 2009, 102, 765-771.	1.8	44
96	Heparin-induced Thrombocytopenia, a Prothrombotic Disease. Hematology/Oncology Clinics of North America, 2007, 21, 65-88.	0.9	43
97	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 1740.	1.0	43
98	Does moderate hypothermia really carry less bleeding risk than deep hypothermia for circulatory arrest? A propensity-matched comparison in hemiarch replacement. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1559-1569.e2.	0.4	41
99	Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Journal of Thrombosis and Haemostasis, 2018, 16, 54-64.	1.9	41
100	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thrombosis Research, 2019, 179, 11-14.	0.8	41
101	Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2007, 105, 570-582.	1.1	40
102	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Critical Care, 2016, 20, 115.	2.5	40
103	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 2302-2309.e6.	0.4	40
104	The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation. Anesthesia and Analgesia, 2002, 95, 26-30.	1.1	39
105	Hereditary Angioedema. Anesthesia and Analgesia, 2010, 110, 1271-1280.	1.1	39
106	Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. Thrombosis Research, 2018, 171, 1-6.	0.8	39
107	Pharmacologic methods to reduce perioperative bleeding. Transfusion, 2008, 48, 31S-38S.	0.8	38
108	Proposal of a twoâ€step process for the diagnosis of sepsisâ€induced disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1265-1268.	1.9	37

#	Article	IF	Citations
109	COVIDâ€19: Thrombosis, thromboinflammation, and anticoagulation considerations. International Journal of Laboratory Hematology, 2021, 43, 29-35.	0.7	37
110	Heparin-induced thrombocytopenia and cardiac surgery. Current Opinion in Anaesthesiology, 2010, 23, 74-79.	0.9	36
111	Point of Care and Factor Concentrate-Based Coagulation Algorithms. Transfusion Medicine and Hemotherapy, 2015, 42, 115-121.	0.7	36
112	Point of Care Devices for Assessing Bleeding and Coagulation in the Trauma Patient. Anesthesiology Clinics, 2013, 31, 55-65.	0.6	35
113	Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 170-174.	1.9	34
114	Low Plasma Fibrinogen Levels with the Clauss Method during Anticoagulation with Bivalirudin. Anesthesiology, 2008, 109, 160-161.	1.3	33
115	Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1020-1026.	0.7	32
116	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Archives of Medical Research, 2021, 52, 788-797.	1.5	32
117	The ideal agent for perioperative hypertension and potential cytoprotective effects. Acta Anaesthesiologica Scandinavica, 1993, 37, 20-25.	0.7	31
118	Hemostatic agents. Transfusion, 2004, 44, 58S-62S.	0.8	31
119	Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. Clinics in Laboratory Medicine, 2014, 34, 537-561.	0.7	31
120	Anticoagulation management associated with extracorporeal circulation. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2015, 29, 189-202.	1.7	31
121	Discontinuation and management of direct-acting anticoagulants for emergency procedures. American Journal of Emergency Medicine, 2016, 34, 14-18.	0.7	31
122	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends in Cardiovascular Medicine, 2022, 32, 1-9.	2.3	31
123	Idarucizumab for dabigatran overdose. Clinical Toxicology, 2016, 54, 644-646.	0.8	30
124	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2022, 50, e80-e86.	0.4	30
125	Aprotinin: A Pharmacologic Overview. Orthopedics, 2004, 27, s653-8.	0.5	29
126	The Judicious Use of Recombinant Factor VIIa. Seminars in Thrombosis and Hemostasis, 2016, 42, 125-132.	1.5	28

#	Article	IF	Citations
127	Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends in Cardiovascular Medicine, 2022, 32, 249-256.	2.3	28
128	Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Nonâ€“vitamin K Anticoagulant Reversal. Anesthesiology, 2018, 129, 1171-1184.	1.3	27
129	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. Annals of Surgery, 2021, 274, e204-e211.	2.1	27
130	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 297-303.	1.9	27
131	The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opinion on Biological Therapy, 2003, 3, 509-517.	1.4	26
132	The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. Frontiers in Immunology, 2020, 11, 2085.	2.2	26
133	The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation, 2020, 27, e12617.	1.0	26
134	The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962092909.	0.7	26
135	The Influence of Various Patient Characteristics on D-dimer Concentration in Critically Ill Patients and Its Role as a Prognostic Indicator in the Intensive Care Unit Setting. Clinics in Laboratory Medicine, 2014, 34, 675-686.	0.7	25
136	Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review. Anesthesia and Analgesia, 2017, 124, 1268-1276.	1.1	25
137	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. International Journal of Emergency Medicine, 2018, 11, 55.	0.6	25
138	Perioperative Management of Patients Receiving New Oral Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, 637-654.	0.7	24
139	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961882404.	0.7	24
140	Evaluation and management of bleeding during cardiac surgery. Psychophysiology, 2005, 4, 368-72.	1.1	24
141	How to manage anticoagulation during extracorporeal membrane oxygenation. Intensive Care Medicine, 2022, 48, 1076-1079.	3.9	24
142	Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery?. Transfusion, 2009, 49, 2006-2007.	0.8	23
143	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. American Heart Journal, 2016, 182, 62-71.	1.2	23
144	Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Critical Care, 2019, 23, 302.	2.5	22

#	Article	IF	Citations
145	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3174-3183.	1.9	22
146	Regulation of Thrombin Activityâ€"Pharmacologic and Structural Aspects. Hematology/Oncology Clinics of North America, 2007, 21, 33-50.	0.9	21
147	Safe Application of a Restrictive Transfusion Protocol in Moderate-Risk Patients Undergoing Cardiac Operations. Annals of Thoracic Surgery, 2014, 97, 1630-1635.	0.7	21
148	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. EClinicalMedicine, 2022, 44, 101276.	3.2	21
149	Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro. Anesthesia and Analgesia, 2020, 130, 1063-1076.	1.1	20
150	Efficacy and Safety of Aprotinin in Cardiac Surgery. Orthopedics, 2004, 27, s659-62.	0.5	20
151	Recombinant Activated Factor VII. Anesthesia and Analgesia, 2011, 113, 711-712.	1.1	19
152	Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. Neurochemical Research, 2015, 40, 2220-2229.	1.6	19
153	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. Critical Care, 2016, 20, 273.	2.5	19
154	What is the evidence for platelet transfusion in perioperative settings?. Vox Sanguinis, 2017, 112, 704-712.	0.7	19
155	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. Research and Practice in Thrombosis and Haemostasis, 2020,	1.0	19
156	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. Journal of Trauma and Acute Care Surgery, 2021, 91, S19-S25.	1.1	19
157	Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 1077-1082.e4.	0.4	18
158	Sepsis-Induced Disseminated Intravascular Coagulation, Symmetrical Peripheral Gangrene, and Amputations. Critical Care Medicine, 2013, 41, e290-e291.	0.4	18
159	Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. Canadian Journal of Anaesthesia, 2016, 63, 1223-1232.	0.7	18
160	3-Factor Prothrombin Complex Concentrates in Infants With Refractory Bleeding After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1627-1631.	0.6	18
161	New Oral Anticoagulantâ€"Induced Bleeding. Clinics in Laboratory Medicine, 2014, 34, 575-586.	0.7	17
162	Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. American Journal of Medicine, 2016, 129, S47-S53.	0.6	17

#	Article	IF	Citations
163	Ischemic limb necrosis in septic shock: What is the role of highâ€dose vasopressor therapy?. Journal of Thrombosis and Haemostasis, 2019, 17, 1973-1978.	1.9	17
164	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. EClinicalMedicine, 2020, 29-30, 100647.	3.2	17
165	Endothelial Injury in COVID-19 and Acute Infections. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1774-1776.	1.1	17
166	Evaluation of patients at risk for protamine reactions. Journal of Thoracic and Cardiovascular Surgery, 1989, 98, 200-4.	0.4	17
167	Platelet Activation and Thrombosis in COVID-19. Seminars in Thrombosis and Hemostasis, 2023, 49, 055-061.	1.5	17
168	Use of Cardiopulmonary Bypass in Studies of the Circulation. British Journal of Anaesthesia, 1988, 60, 35S-37S.	1.5	16
169	Effects of protamine on histamine release from human lung. Agents and Actions, 1989, 28, 70-72.	0.7	16
170	A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass. Anesthesia and Analgesia, 2012, 115, 1273-1278.	1.1	16
171	Threeâ€factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis, 2019, 114, 374-385.	0.7	16
172	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2400-2407.	1.9	16
173	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. International Journal of Hematology, 2021, 113, 330-336.	0.7	16
174	New concepts in the treatment of anaphylactoid reactions in anesthesia. Annales Francaises D'Anesthesie Et De Reanimation, 1993, 12, 223-227.	1.4	15
175	Anaphylactic Reactions to Neuromuscular Blocking Drugs: Are We Making the Correct Diagnosis?. Anesthesia and Analgesia, 2004, 98, 881-883.	1.1	15
176	Management of systemic and pulmonary hypertension. Texas Heart Institute Journal, 2005, 32, 467-71.	0.1	15
177	Etiology and Assessment of Hypercoagulability with Lessons from Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2011, 112, 46-58.	1.1	14
178	COVID-19â€“associated Coagulopathy. Anesthesiology, 2021, 134, 366-369.	1.3	14
179	Hemostatic agents and their safety. Journal of Cardiothoracic and Vascular Anesthesia, 1999, 13, 6-11; discussion 36-7.	0.6	14
180	Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery:post hocanalysis and interpretation of phase III results. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 566-574.	0.5	13

#	Article	IF	Citations
181	Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. American Journal of Health-System Pharmacy, 2005, 62, S15-S19.	0.5	12
182	Anti-inflammatory Strategies and Hemostatic Agents: Old Drugs, New Ideas. Hematology/Oncology Clinics of North America, 2007, 21, 89-101.	0.9	12
183	Impact of Perioperative Blood Pressure Variability on Health Resource Utilization After Cardiac Surgery: An Analysis of the ECLIPSE Trials. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 579-585.	0.6	12
184	Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal Agent. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 265-266.	0.6	12
185	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	1.0	12
186	Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021). Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100919.	0.6	12
187	Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. Journal of Thrombosis and Haemostasis, 2006, 4, 1875-1878.	1.9	11
188	The anticoagulated patient: Strategies for effective blood loss management. Surgery, 2007, 142, S71-S77.	1.0	11
189	Protocol Adherence When Managing Massive Bleeding Following Complex Cardiac Surgery: A Study Design Pilot. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 303-310.	0.6	11
190	Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy?. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1849-1856.	0.6	11
191	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 145S-149S.	0.7	11
192	Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. Blood Advances, 2021, 5, 613-627.	2.5	11
193	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. Thrombosis and Haemostasis, 2022, 122, 008-019.	1.8	11
194	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. Blood Coagulation and Fibrinolysis, 2021, 32, 544-549.	0.5	11
195	Safety of aprotinin in heparinized and nonheparinized patients. Journal of Cardiothoracic and Vascular Anesthesia, 2004, 18, S38-S42.	0.6	10
196	Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. International Journal of Molecular Sciences, 2021, 22, 176.	1.8	10
197	Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant. JAMA Surgery, 2022, 157, e215856.	2.2	10
198	Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thrombosis and Haemostasis, 2005, 94, 808-13.	1.8	9

#	Article	IF	Citations
199	Should aprotinin continue to be used during cardiac surgery?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 360-361.	3.3	9
200	Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?. A&A Practice, 2019, 13, 477-477.	0.2	9
201	Using Plasma and Prothrombin Complex Concentrates. Seminars in Thrombosis and Hemostasis, 2020, 46, 032-037.	1.5	9
202	Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. Trends in Cardiovascular Medicine, 2021, 31, 6-7.	2.3	9
203	Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction. Journal of Alzheimer's Disease, 2021, 80, 1281-1297.	1.2	9
204	Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. Annals of Thoracic Surgery, 2022, 113, 1026-1035.	0.7	9
205	Diagnosis and treatment of anaphylactic/anaphylactoid reactions. Monographs in Allergy, 1992, 30, 130-44.	0.2	9
206	Heparin resistance and the potential impact on maintenance of therapeutic coagulation. European Journal of Anaesthesiology, 2007, 24, 37.	0.7	8
207	Pharmacology and Safety of New Oral Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, 443-452.	0.7	8
208	Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. Anesthesiology, 2022, 137, 67-78.	1.3	8
209	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ„¢ study. Journal of Medical Economics, 2017, 20, 435-442.	1.0	7
210	Protamine, is something fishy about it? The spectre of anaphylaxis continues. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 487-488.	0.6	7
211	How to interpret recent restrictive transfusion trials in cardiac surgery: More new data or new more data?. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1038-1040.	0.4	7
212	The authors reply. Critical Care Medicine, 2020, 48, e1160-e1161.	0.4	7
213	Hypercoagulability and coronavirus disease 2019â€“associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. Journal of Trauma and Acute Care Surgery, 2020, 89, e177-e181.	1.1	7
214	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Medica, 2022, 112, .	0.3	7
215	Off-Label Use of Recombinant Human Factor VIIa. Annals of Thoracic Surgery, 2014, 98, 393-395.	0.7	6
216	Precision Correction of Coagulopathy or Prothrombin Complex Concentrates?. Anesthesiology, 2017, 127, 744-746.	1.3	6

#	Article	IF	Citations
217	Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary bypass surgery by utilizing two scoring systems. Blood Coagulation and Fibrinolysis, 2019, 30, 11-16.	0.5	6
218	Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study. Thrombosis Research, 2021, 205, 8-10.	0.8	6
219	Anesthetic concerns for patients with coagulopathy. Current Opinion in Anaesthesiology, 2010, 23, 400-405.	0.9	5
220	Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. Transfusion Medicine Reviews, 2017, 31, 258-263.	0.9	5
221	Restarting Therapeutic Anticoagulation After Elective Craniotomy for Patients with Chronic Atrial Fibrillation: A Review of the Literature. World Neurosurgery, 2020, 137, 130-136.	0.7	5
222	Novel pharmacologic approaches to reduce bleeding. Canadian Journal of Anaesthesia, 2003, 50, S26-30.	0.7	5
223	Tranexamic Acid for Acute Hemorrhage. Anesthesia and Analgesia, 2019, 129, 1459-1461.	1.1	4
224	More on Venous Thrombosis during Spaceflight. New England Journal of Medicine, 2020, 382, 1381-1382.	13.9	4
225	Perioperative Thrombosis and Hemostasis. Seminars in Thrombosis and Hemostasis, 2020, 46, 006-007.	1.5	4
226	Role of Coagulation Factor Concentrates for Reversing Dabigatran-related Anticoagulation. Anesthesiology, 2014, 120, 1316-1318.	1.3	4
227	Protocolized hemostatic factor use in major thoracic aortic surgery. Journal of Cardiovascular Surgery, 2019, 60, 633-636.	0.3	4
228	The Predictive Value of the 4Ts and HEP Score at Recommended Cutoffs in Patients With Mechanical Circulatory Support Devices. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	4
229	Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials. British Journal of Anaesthesia, 2018, 120, 407-409.	1.5	3
230	Cryoprecipitate transfusion in bleeding patients. Canadian Journal of Emergency Medicine, 2020, 22, S4-S11.	0.5	3
231	Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx. JTCVS Techniques, 2020, 4, 154-155.	0.2	3
232	Interpreting recent clinical studies for COVID-19: A continual process with more new data. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101016.	0.6	3
233	Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery. Seminars in Hematology, 1995, 32, 49-55.	1.8	3
234	The risk of thromboembolic events with early intravenous 2â€•and 4â€g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, doubleâ€blind, placeboâ€controlled, singleâ€center trial. Transfusion, 2022, 62, .	0.8	3

#	Article	IF	Citations
235	A modified recombinant factorÂVIIa: can we make it work Harder, Better, Faster, Stronger?. Journal of Thrombosis and Haemostasis, 2009, 7, 1514-1516.	1.9	2
236	Effects of blood storage age on immune, coagulation, and nitric oxide parameters in transfused patients undergoing cardiac surgery. Transfusion, 2019, 59, 1209-1222.	0.8	2
237	A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. Journal of Critical Care, 2021, 64, 108-113.	1.0	2
238	Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding. Blood, 2016, 128, 5035-5035.	0.6	2
239	Perioperative experience with amrinone. European Journal of Anaesthesiology Supplement, 1992, 5, 15-9.	0.2	2
240	Anaphylaxis. What is monitored to make a diagnosis? How is therapy monitored?. Anesthesiology Clinics, 2001, 19, 705-15.	1.4	2
241	Management of surgical hemostasis: systemic agents. Vascular, 2008, 16 Suppl 1, S14-21.	0.4	2
242	Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis. Thrombosis Research, 2022, 216, 106-112.	0.8	2
243	Dabigatran-related coagulopathy: when can we assume the effect has â€œworn offâ€?. American Journal of Emergency Medicine, 2014, 32, 1433-1434.	0.7	1
244	Novel oral anticoagulation agents: New drugs create new paradigms. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1802-1803.	0.4	1
245	Editorial Comment. A & A Case Reports, 2014, 2, 95.	0.7	1
246	Protamine reversal of heparin: a fishy practice?. Europace, 2019, 21, 840-841.	0.7	1
247	Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation. Anesthesiology, 2019, 131, 459-461.	1.3	1
248	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsisâ€induced coagulopathy than fibrinâ€related markers: Response to the Letterâ€toâ€theâ€Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	1.9	1
249	Key Pathogenic Factors in Coronavirus Disease 2019â€“Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. A&A Practice, 2021, 15, e01432.	0.2	1
250	Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.. Blood, 2010, 116, 1108-1108.	0.6	1
251	Prothrombin Complex Concentrates and Cardiac Surgery. Blood, 2015, 126, 4712-4712.	0.6	1
252	Thrombin Generation in Cardiac Versus Noncardiac Surgical Cohorts. Anesthesia and Analgesia, 2022, 134, 606-614.	1.1	1

#	Article	IF	Citations
253	Anaphylactic reactions. Canadian Journal of Anaesthesia, 1992, 39, 95-95.	0.7	0
254	In reply. Transfusion, 2014, 54, 1443-1444.	0.8	0
255	Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, xiii-xv.	0.7	0
256	Factor Concentrates for Perioperative Bleeding. Anesthesia and Analgesia, 2015, 121, 4-5.	1.1	0
257	Editorial Comment. A & A Case Reports, 2015, 4, 125-126.	0.7	0
258	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	1.3	0
259	Edoxaban in the secondary prevention of VTE. Lancet Haematology,the, 2016, 3, e208-e209.	2.2	0
260	Journal-related Activities and Other Special Activities at the 2018 American Society of Anesthesiologists Meeting. Anesthesiology, 2018, 129, 634-643.	1.3	0
261	Perioperative coagulation management: Evolving strategies. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 317-318.	0.6	0
262	Use of factor concentrates for the management of perioperative bleeding: reply. Journal of Thrombosis and Haemostasis, 2018, 16, 2113-2115.	1.9	0
263	Blood and Coagulation. , 2019, , 837-848.		0
264	The authors reply. Critical Care Medicine, 2020, 48, e989-e990.	0.4	0
265	The Contact Activation System: Problems and Paradoxes for Cardiac Anesthesiologists. Anesthesia and Analgesia, 2020, 131, 152-154.	1.1	0
266	In Response. Anesthesia and Analgesia, 2020, 130, e154-e156.	1.1	0
267	Commentary: Patient blood management in the era of coronavirus disease 2019â€"is anything really different?. JTCVS Open, 2021, 5, 97-98.	0.2	0
268	Viscoelastic testing to assess the effects of rapid fibrinogen concentrate administration after cardiopulmonary bypass: insights from the REPLACE study. Blood Coagulation and Fibrinolysis, 2021, 32, 359-365.	0.5	0
269	Heated Humidified Breathing Circuit Rewarming in Hypothermic Patients Post-Cardiopulmonary Bypassâ€"Pilot Study. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	0.6	0
270	Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2021, Publish Ahead of Print, .	0.4	0

#	Article	IF	Citations
271	Coagulopathy and Bleeding Management for Aortic Dissection Surgery. , 2021, , 577-593.		0
272	Can We Use Viscoelastic Testing to Evaluate Microvascular Dysfunction in Acute Myocardial Infarction?. JACC Basic To Translational Science, 2021, 6, 762-764.	1.9	0
273	Lack of Clinically Significant Interactions Between the Subcutaneously Administered Direct Thrombin Inhibitor Desirudin and Orally Administered Warfarin Upon the International Normalized Ratio.. Blood, 2009, 114, 3131-3131.	0.6	0
274	VTE Prophylaxis with Desirudin in Patients with Thrombocytopenia: Insights From the DESIRABLE Trial,. Blood, 2011, 118, 3293-3293.	0.6	0
275	In Reply. Anesthesiology, 2014, 120, 243-243.	1.3	0
276	Post Hoc Analysis of Desirudin Versus Enoxaparin for Thromboprophylaxis in High-Risk Patients Undergoing Elective Hip Replacement Surgery. Blood, 2014, 124, 5086-5086.	0.6	0
277	Management of Chronically Anticoagulated Patients. , 2016, , 529-542.		0
278	Management of Chronically Anticoagulated Patients. , 2021, , 663-676.		0
279	Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. Journal of Intensive Care, 2022, 10, 4.	1.3	0
280	ECMO Outcomes, Transfusions, and Hemostatic Management: Quo Vadis?. Annals of Thoracic Surgery, 2022, , .	0.7	0